Bruker Corp

BRKRNASDAQ · USD
60.62USD-0.97 (-1.58%)
5910

Bruker Corp (BRKR) Covered Calls

Bruker Corp trades in the Medical Devices industry with an IV Rank of 41.47%, average versus the past year. BRKR's highest covered call setup is the $70.00 strike expiring Nov 20, 2026, sorted by theoretical annualized return. It's 12.16% out of the money with 9 days to expiration, a 12.32% return until expiration, and a 499.72% theoretical annualized return. Across the setups shown, annualized returns run from 122.82% to 499.72% at strikes between $62.50 and $95.00, with 9 to 128 days to expiration, as of Nov 11, 2026.

Read more

Running BRKR covered calls helps you generate income from Bruker Corp shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best BRKR covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call pairs limited risk with a clear income profile. If BRKR stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling BRKR covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given BRKR covered call is worth writing.

Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits.

2026-11-20970.0012.160.100.95769.0012.32499.72-0.16+0.163790.85
2026-12-183785.0036.200.052.202264.0036.28357.86-0.08+0.151772.15
2026-11-20967.508.160.101.20519.008.32337.26-0.16+0.2161.10
2026-11-20965.004.151.152.05374.005.99243.03-1.84+0.371,1440.90
2026-12-183775.0020.170.202.801279.0020.49202.17-0.32+0.227642.60
2026-12-183772.5016.170.503.301059.0016.97167.39-0.80+0.2702.80
2027-03-1912895.0052.220.502.553309.0053.02151.19-0.80+0.1602.05
2026-12-183770.0012.161.202.50879.0014.08138.94-1.92+0.29461.30
2027-03-1912890.0044.211.153.102874.0046.05131.32-1.84+0.20421.95
2026-11-20962.500.141.804.10189.003.03122.82-2.88+0.525912.30

As of Nov 11, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →

Stock Statistics

  • IndustryMedical Devices
  • SectorHealthcare
  • IV Rank41.47% Moderate
  • Market cap (M$)9,406
  • 52 weeks high-10.71%
  • 52 weeks low90.33%
  • Analyst recommendationBuy
    2.36
  • Target price$68.00
    12.17% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2027-02-11
  • P/E—
  • Future P/E25.25
  • EPS (ttm)-1.10
  • EPS growth next 5 years15.31%

As of Nov 13, 2026